PTA-News: Darwin AG: Share Split in a 1:3 Ratio Implemented
Refinitiv阅读1分钟
Darwin AG
by Daniel Wallerstorfer
Business news for the stock market Munich, September 18, 2025 (pta/18.09.2025/15:10) - The share split in a ratio of 1:3, resolved by the extraordinary general meeting of Darwin AG (ISIN DE000A3C35W0) on August 13, 2025, will be implemented as of today. Trading on the stock exchange today takes place ex adjustment shares. All existing shareholders who held shares of Darwin AG as of yesterday will, by September 22, 2025, receive three new shares for each share held. Since shareholders' rights to securitization of their holdings are excluded pursuant to § 4 (4) of the Articles of Association, and all of the company's shares are held in collective custody accounts, shareholders do not need to take any action regarding the allocation of bonus shares. The allocation of bonus shares will be carried out for eligible shareholders based on their holdings of old no-par value shares on the record date by means of collective custody account credit. The record date for determining eligible holdings is September 19, 2025. The record date for the crediting of bonus shares is September 22, 2025. About Darwin AG The 'Darwin Group' (i.e., Darwin AG including its subsidiaries and sub-subsidiaries), headquartered in Munich (Germany), is a European biotechnology company specializing in human genetics. The genetic analyses carried out in its own laboratory are used in the diagnosis, therapy, and prevention of diseases as well as in the production of individually designed nutritional supplements and cosmetics. Darwin also acts as a partner for doctors, therapists, pharmacists, nutritionists, or fitness trainers, and helps to ensure the most optimal treatment or care for the patient or client by analyzing their respective genetic predisposition. In addition, Darwin invests in innovative companies in the fields of biotech, healthcare, and life sciences. (end) emitter: Darwin AG address: Brienner Straße 7, 80333 München country: Germany contact person: Daniel Wallerstorfer phone: +49 89 20 500 450 e-mail: investor.relations@darwin-biotech.com website: www.darwin-biotech.com ISIN(s): DE000A3C35W0 (share) stock exchanges: open market (free market) in Frankfurt, m:access in Munich pressetext Nachrichtenagentur GmbH Ad-hoc and financial news distributed by pressetext.adhoc. Archive: http://adhoc.pressetext.com The emitter is responsible for the content. Contact: adhoc@pressetext.com or +43-1-81140-0.
登录或创建永久免费帐户以阅读此新闻